Sansure Biotech Inc (688289): Kapitalflussrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 15,9 Renminbi Yuan | 22,509 Renminbi Yuan | 13,4 Renminbi Yuan |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 22,02 Renminbi Yuan | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 574.937.804 | - | - |
Kennzahl in 1000 CNY | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
Umsatz | 1.648.244 | 1.458.061,552 | 1.007.118,933 | 6.450.356,637 | 4.514.539,266 | 4.762.963,902 | 365.389,084 | 303.446,306 | 224.596,51 |
Cashflow aus operativer Geschäftstätigkeit | 183.960,844 | 274.447,856 | 112.821,114 | 2.558.946,923 | 1.877.070,615 | 2.642.276,432 | 22.405,731 | 10.067,12 | -61.444,859 |
▸ Operative Cashflow Marge | 11,16% | 18,82% | 11,2% | 39,67% | 41,58% | 55,48% | 6,13% | 3,32% | -27,36% |
Investitionsausgaben (CapEx) | 369.767,236 | 421.104,874 | 391.349,714 | 558.828,106 | 372.863,882 | 108.665,825 | 34.141,346 | 32.904,897 | 20.685,957 |
Cashflow aus Investitionstätigkeit | - | -101.921,604 | 1.397.789,976 | -1.166.746,227 | -1.112.221,045 | -1.715.956,9 | -94.600,101 | 77.516,266 | -65.746,106 |
Cashflow aus Finanzierungstätigkeit | - | 132.490,649 | -529.110,046 | -915.948,041 | -688.590,633 | 1.609.900,688 | 44.394,112 | - | 147.331,242 |
Freier Cashflow | -185.806,392 | -146.657,018 | -278.528,6 | 2.000.118,817 | 1.504.206,733 | 2.533.610,607 | -11.735,615 | -22.837,777 | -82.130,816 |
▸ Freie Cashflow Marge | -11,27% | -10,06% | -27,66% | 31,01% | 33,32% | 53,19% | -3,21% | -7,53% | -36,57% |
Ausgeschüttete Dividenden | -333.680,98 | -268.401,272 | -400.074,755 | -647.239,06 | -449.310 | -300.000 | - | - | -5.583,411 |
Neuausgabe und Rückkäufe von Stammaktien | - | - | -122.733,637 | -257.408,119 | -200.009,829 | - | - | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.